Enveric Biosciences, Inc.

As of March 31, 2022, Enveric Biosciences, Inc. is considered overvalued with deteriorating financial metrics, including a high ROCE of 963.23% but a negative ROE of -245.58%, and has significantly underperformed its peers and the S&P 500, with a year-to-date return of -76.75%.

As of April 21, 2025, Enveric Biosciences, Inc. shows a mildly bearish trend, with daily moving averages indicating bearish momentum, while weekly indicators suggest mild bullishness, resulting in a moderate overall bearish stance influenced by recent price action and underperformance compared to the S&P 500.

Enveric Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $3.09 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -245.58%.

As of Jun 18, Enveric Biosciences, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million with a net profit of -9.29 million over the last four quarters. Shareholder's funds are 1.59 million and total assets are 3.08 million as of Dec 24.